Potential strategies for an HIV infection cure

HIV Clinical Trials

Volumn 12, Issue 3, 2011, Pages 121-130

  Lafeuillade, Alain ^a  

^a GENERAL HOSPITAL   (France)

Author keywords

HIV cure; HIV persistence; HIV reservoirs

Indexed keywords

CHEMOKINE RECEPTOR CCR5; ZIDOVUDINE;

ACUTE DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL GENE THERAPY; VIRUS LATENCY; WESTERN BLOTTING;

ANTI-HIV AGENTS; DNA, VIRAL; GENE THERAPY; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5;

EID: 79959415122     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1203-121     Document Type: Review

References (57)

1. Moir S, Chun TW, Fauci AS. Pathogenesis mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223-248
2. Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N. Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc. 2011;14(1):4. [Epub ahead of print]
3. Onen NF, Overton ET. A review of premature frailty in HIVinfected persons; another manifestation of HIV-related accelerated aging. Curr Aging Sci. 2011;4(1):33-41
4. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155
5. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24(9): 1367-1370
6. Brew BJ. Benefi t or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis. 2010;50(6):930-932
7. Richman DD. Introduction: challenges to fi nding a cure for HIV infection. Curr Opin HIV AIDS. 2011;6(1):1-3
8. Keedy KS, Kashuba AD, Margolis DM. Therapy for persistent HIV. Trends Pharmacol Sci. 2010;31(5):206-211
9. Pace MJ, Agosto L, Graf EH, ODoherty U. HIV reservoirs and latency models. Virology. January 31, 2011 [Epub ahead of print]
10. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIVinfected individuals. Science. 2010;329(5988):174-180
11. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009;6:111
12. Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep. 2010;7: 37-43
13. Onafuwa-Nuga A, McNamara LA, Collins KL. Toward a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res. 2010;20(11):1185-1187
14. Alexaki A, Liu Y, Wigdahl. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008;6:388-400
15. Crowe S. Macrophages and residual HIV infection. Curr Opin HIV AIDS. 2006;1(2):129-133
16. Gavegnano C, Schinazi R. Antiretroviral therapy in macrophages: implications for HIV eradication. Antivir Chem Chemother. 2009;20(2):63-78
17. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIVassociated cognitive impairment, infl ammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5):625-633
18. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, infl ammation, and neuronal injury in an era of highly active antiretroviral treatment. AIDS. 2011;25(5):625-633
19. Lafeuillade A, Khiri H, Chadapaud S, Hittinger G, Halfon P. Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART. AIDS. 2001;15(15):1965-1969 (Pubitemid 32980638)
20. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol. 2010;84(6):2913-2922
21. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensifi cation does not reduce persistent lowlevel viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912-919
22. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensifi cation of HAART-suppressed subjects. Nat Med. 2010;16(4):460-465
23. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravircontaining intensifi cation on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24(16):2451-2460
24. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70
25. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodefi ciency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80(13):6441-6457 (Pubitemid 43927447)
26. Anderson JA, Archin NM, Ince W, et al. Clonal sequences recovered from residual HIV-1 viremia in patients on intensifi ed antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CDA+ T cells. J Virol. March 2, 2011 [Epub ahead of print]
27. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathogens. 2011;7(2):e1001303
28. Lerner P, Guadalupe M, Donovan R, et al. Gut mucosal viral reservoir in HIV infected patients is not the major source of rebound plasma viremia following HAART interruption. J Virol. February 23, 2011 [Epub ahead of print]
29. McMichael A, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10(1):11-23
30. Kinloch-de Loes S. Treatment of acute HIV-1 infection: Is it coming of age? J Infect Dis. 2006;194:721-724 (Pubitemid 44344117)
31. Bell SK, Little SJ, Rosenberg ES. Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis. 2010;202(Suppl 2):S278-288
32. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Longterm immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24(10):1598-1601
33. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis. 2003;188(10):1426-1432 (Pubitemid 37523927)
34. Koelsch K, Boeseke C, Fahey P, et al. RAL in combination with tenofovir and emtricitabine during primary and chronic HIV infection: impact on HIV RNA and DNA in peripheral blood and gut mucosal tissue. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 280
35. Ananworanich J, Schuetz A, Sereti I, et al. Mega-HAART suppresses HIV viremia, reduces viral reservoir, and restores immunity in peripheral blood and sigmoid colon of acute HIV-infected subjects. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 516
36. Markowitz M, Evering T, Caskey M, et al. A randomized open-label trial of 5-drug vs 3-drug standard PI-based cART initiated during acute and early HIV-1 infection: 48-week results. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 148LB
37. Choudhary SK, Margolis DM. Curing HIV: pharmacologic approaches to target HIV-1 latency. Ann Rev Pharmacol Toxicol. 2011;51:397-418
38. Lafeuillade A. Translational eradication approaches. Curr Opin HIV AIDS. 2006;1(2):141-146
39. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of fi nding a cure for HIV infection. Science. 2009;323(5919):1304-1307
40. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7(11):798-812
41. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893-900
42. Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS. 2010 Dec 14. [Epub ahead of print]
43. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010;24:2803-2808
44. Berger EA. Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS. 2011;6(1):80-85
45. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathogens. 2010;6(6):e1000803
46. Kitchen SG, Shimizu S, An DS. Stem cell-based anti-HIV gene therapy. Virology. 2011 Jan 17. [Epub ahead of print]
47. Htter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-698
48. Deeks SG, Mc Cune M. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010;28(8):807-810
49. Allers K, Htter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood. December 8, 2010 [Epub ahead of print]
50. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modifi ed by zinc-fi nger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010;28(8):839-849
51. Lalezari J, Mitsuyasu R, Deeks S, et al. Successful and persistent engraftment of ZFN-M-R5-D autologous CD4 T Cells (SB-728-T) in aviremic HIV-infected subjects on HAART. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 46
52. Tebas P, Levine B, Binder G, et al. Disruption of CCR5 in zinc fi nger nuclease-treated CD4 T cells: phase I rrials. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 165
53. Cannon P, Holt N, Hofer U, et al. CCR5 knock-out in hematopoietic stem cells. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 164
54. Wilen C, Wang J, Tilton J, et al. Creating an HIV-resistant immune system: using CXCR4 ZFN to edit the human genome. In: Program and abstracts from the 18th Conference on Retroviruses and Opportunistic Infection; February 27-March 2, 2011; Boston, MA. Abstract 47
55. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modifi ed CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36-43
56. Van Lunzen J, Fehse B, Hauber J. Gene therapy strategies: Can we eradicate HIV? Curr HIV/AIDS Rep. February 18, 2011 [Epub ahead of print]
57. Margolis DM. Eradication therapies for HIV infection: time to begin again. AIDS Res Hum Retroviruses. February 11, 2011 [Epub ahead of print]